Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Biomea Fusion, Inc.

MOMA Therapeutics focuses on discovering the next generation of precision medicines by targeting the molecular machines underlying human disease.

MOMA Therapeutics

Prenosis develops precision medicine tools and implements them in real time for acute care settings, focusing on personalizing healthcare based on individual biology. They leverage their Immunix precision medicine platform and have created the FDA authorized Sepsis ImmunoScore.

Prenosis

Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.

Biomea Fusion, Inc. Common Stock

Biomea Fusion is a clinical-stage biopharmaceutical company focused on discovering and developing oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers.  Biomea Fusion's lead investigational compound, BMF-219, is a covalent menin inhibitor.  The company also develops BMF-500, a covalent FLT3 inhibitor.

Metric
Company Name	Biomea Fusion, Inc.	MOMA Therapeutics	Prenosis
Symbol	BMEA
MSH ID	COM:BIOMEAFUSION	COM:MOMATX	COM:PRENOSIS
Market	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Biotechnology
Country	US	US	US
Stage		Series B	Grant
Employee Count	110
Website	biomeafusion.com	momatx.com	prenosis.com
LinkedIn			prenosis
Founders

Metric
Market Cap	170.74M
Enterprise Value
Monthly Web Traffic		2.27K	1.15K
Web Traffic Growth		0.12	46.92
Valuation
Raised Capital		150M	4.80M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:BIOMEAFUSION

Biomea Fusion

Last Close

6.38

22/11 21:00

Market Cap

145.32M

Beta: -

Volume Today

490.54K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue